甲孕酮合并化疗改善晚期肺癌患者生活质量的临床观察  

Clinical observation of medroxyprogesterone acetate improving the life quality of lung cancer patients in chenmotherapy

作　　者：白羽[1] 刘叙仪[2] 吴梅娜[2] 方健[2] 

机构地区：[1]北京大学第一医院化疗科 [2]北京大学临床肿瘤学院,邮政编码100037

出　　处：《北京医学》2000年第6期346-349,共4页Beijing Medical Journal

摘　　要：目的　观察患者服用甲孕酮后改善化疗所致的厌食、体重下降、ECOG下降、骨髓抑制及胃肠道反应的作用及止痛和促进蛋白同化作用。方法　 130例接受化疗的晚期肺癌患者 ,分成单用化疗组及化疗 +甲孕酮组。结果　在化疗 +甲孕酮组治疗的 160个周期中有 4 3.1%食量增加 ;4 5%体重增长 ,平均每周期体重增加 0 .74± 1.56kg;血浆白蛋白升高 1.2± 2 .9g/ L、88.1%疼痛减轻及 2 8.1% ECOG改善。化疗的毒副作用 ,出现 度以上的白细胞下降占 33.8%、血红蛋白下降占 15.6%及胃肠道反应占 18.1%。结论　甲孕酮如能正确合理地用于晚期癌症的治疗 ,可以全面改善化疗期癌症患者的生活质量。Objective To investigate the improving effect of medroxyprogesterone acetate (MPA) on anorexia,weight loss,decreasing life quality,myelosuppression as well as nausea and vomiting caused by chemotherapy.The effection of MPA on alleviation of cancerous pain and promotion of albumen assimilation.Methods One hundred and thirty patients with advanced lung cancer received chemotherapy (CT) were divided randomly into two groups:chemotherapy alone and chemotherapy plus MPA.Results The patients who were given with 160 cycles of plus CT MPA had increased food intake in 43.13% of cycles,weight gain in 45% of cycles with an average of 0.74±1.56kg up,blood albumin rise 1.2±2.9g/L in average,ECOG improvement in 28.1% of cycles as well as cancerous pain abatement in 88.1% of cycles.According to WHO criteria,there were grade Ⅱ or greater leukopenia in 33.8%,anemia in 15.6% of cycles.There was vomiting in 18.1% of cycles.Conclusions MPA can improve the life quality of patients with advanced lung cancer in chemotherapy.

关 键 词：晚期肺癌 药物疗法 甲孕酮 化疗 生活质量 

分 类 号：R734.205[医药卫生—肿瘤]